Short answer
Replimune Group, Inc. (REPL) filed its Q2 2026 10-Q quarterly report on Aug 14, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$70M
- +19.5% YoY
- EPS (diluted)
- −$0.72
- +24.2% YoY
Source: XBRL data from the Replimune Group, Inc. (REPL) Q2 2026 10-Q on SEC EDGAR. USD.
Replimune Group, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New commercialization risk triggered by August 2026 FDA approval: limited launch experience for TUDRIQEV in combination with nivolumab
- Regulatory risk: accelerated approval depends on IGNYTE-3 and other confirmatory studies verifying clinical benefit
- Operational risk: significant sales and marketing reductions after April 2026’s second CRL may hinder launch readiness
- Market risk: physician adoption may remain limited pending longer-term TUDRIQEV efficacy and safety data
- Financial risk: additional funding may be required because product revenue has not yet been generated
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Replimune Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.